Dr. Andrew S. Thompson, GlobalData’s Senior Analyst Covering In Vitro Diagnostics, states: “Myriad Genetics enjoys a monopoly over the predictive breast cancer gene testing market in the US and elsewhere, but the company’s dominance is set to be challenged during the next few years.”
Myriad Genetics currently has exclusivity in the US, Japan and Brazil to provide testing for the most common breast cancer gene mutations, BRCA1/2, and also has a major presence in the EU. The company’s product, BRACAnalysis, accounted for 83%, or US$351m, of all breast cancer gene test revenue in 2011 across the US, the UK, France, Germany, Italy, Spain, Japan, China, India and Brazil.
The US represents the largest predictive breast cancer gene testing market, and Myriad Genetics’ intellectual property rights mean that opportunities for new market entrants are restricted to non-BRCA testing, which constitutes only 1% of the region’s gene testing market. However, 2015–2018 will mark the expiry of several patents and licenses relating to Myriad Genetics’ flagship BRACAnalysis gene test, opening up competition in the US.
For Sample Pages, please click or add the below link to your browser:
Myriad Genetics’ patents are less enforced abroad, and new opportunities are already present for BRCA tests in Europe. Dr. Thompson states: “Myriad Genetics hopes to expand in Europe, but the market consists of many players who are currently offering tests, while infringing Myriad Genetics’ patents. The last 12 months have seen DNA Sequencer manufacturers make significant acquisitions of niche genetic testing laboratories, in an apparent move to compete in the clinical genetic testing market, representing a potential threat to Myriad Genetics.”
China offers the greatest breast cancer gene testing market opportunities, with the large population suffering rising numbers of breast cancer cases as lifestyles change. The country’s relatively advanced healthcare industry allows for significant growth in genetic testing processes, whereas Brazil and India hold limited opportunities due to a lack of affordable healthcare. However, a great need arises for low-cost gene testing at a community level in India, based on a breast cancer mutation prevalent in the Indian population.
While some physicians might remain loyal to Myriad Genetics, competing companies may offer panel tests, which simultaneously test for several different mutations, reducing investigatory time and increasing cost effectiveness. These may be key factors in a product’s success in emerging economies and cashstrapped European state healthcare systems.
GlobalData estimates that the global predictive breast cancer gene testing market will grow significantly, from US$422m in 2011 to US$1 billion by 2018 at a Compound Annual Growth Rate (CAGR) of 14%.
This report provides information on the breast cancer gene testing market, including diagnosis rates, patient segmentation, treatment rates, procedure volumes, average selling prices, and market values over a 10 year period (2009-2018).
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com/
For more details contact:pressreleases@
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782